The Site Might Experience Some Downtime In The Next 48 hours As We are Further Upgrading Our Servers And Also Installing New Technical Features. We Apologise For Any Inconvenience.

PR Releases
Source: Janssen Pharmaceutical Companies of Johnson & Johnson  Nov 25, 2019  5 months ago
Results from the Phase 3 pivotal trial, showed that more than 40 percent of patients receiving STELARA subcutaneous (SC) injections every 8 weeks were in clinical remission at one year and not taking corticosteroids   STELARA is the first and only approved treatment for ulcerative colitis to demonstrate improvement of the colon as measured by a novel histologic-endoscopic mucosal improvement ...
Source: ECOG-ACRIN CANCER RESEARCH GROUP  Oct 22, 2019  6 months ago
The BRACELET-1 (PrE0113) study seeks to confirm predictive and prognostic biomarkers demonstrating pelareorep can expand application of checkpoint inhibitors in HR+-metastatic breast cancer.                                                    October 22, 2019 -- Oncolyt...
HIMSS Asia Pacific  Oct 01, 2019  6 months ago
For Immediate Release Healthcare and Information Management Systems Society Asia Pacific (HIMSS APAC) and Elsevier are proud to announce the finalists for the Asia Pacific HIMSS-Elsevier Digital Healthcare Award, which identify organizations that have effectively used information and technology to successfully improve quality of health and care and patient safety. The achievements of the organi...
Source: Kiniksa Pharmaceuticals  Aug 06, 2019  8 months ago
Press Release Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company today announced a collaboration with the Myocarditis Foundation in support of patients affected by pericarditis with heart muscle inflammation. Kiniksa and the Myocarditis Foundation are working together to raise awareness about pericarditis, a painful and debilitating autoinflammatory cardiovascular disease. Approximately...
Source: AMGEN  Jul 09, 2019  9 months ago
Amgen announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL). The study found that with a median follow-up of 59.8 months, the median OS for BLINCYTO-treated patients was 36.5 months (95 percent CI: 22 months - n...
Source: Novartis  May 01, 2019  11 months ago
  Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan Agreement is third announced biosimilars collaboration for San...
Source: Thermo Fisher Scientific  Apr 17, 2019  12 months ago
Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific CEDIA Mitragynine (Kratom) Assay, its newest drugs of abuse test that includes supporting calibrators and controls. The CEDIA Mitragynine (Kratom) Assay can be run on commonly used clinical chemistry analyzers, allowing a broad spectrum of laboratorians to test for the presenc...
Source: Allergan  Mar 11, 2019  1 year ago
- Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine - - Allergan Continues to Expand Its Leading Migraine Portfolio Across the Spectrum of the Disease from Episodic to Chronic –   March 11, 2019  Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) ha...
Takeda Pharmaceutical Company   Feb 15, 2019  1 year ago
– ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Demonstrated 29-Percent Reduction in the Risk of Progression, Death or Need for Additional Anticancer Therapy for CD30+ Stage IV Patients   – Milestone Marks Fifth Approved Indication for ADCETRIS in Europe, Reinforcing Takeda’s Commitment to Developing Innovative Solutions for People Li...
Source: Eli Lilly and Company  Jan 20, 2019  1 year ago
REACH-2 is the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population known for poor prognosis   Pooled data analyses of AFP-High patients in the REACH-2 and REACH trials showed an improvement of 3.1 months in median overall survival   Eli Lilly and Company (NYSE: LLY) announced that results from the global Phase 3 REACH-2 study of CYRAMZA® (ra...
Source: Natera  Jan 07, 2019  1 year ago
AstraZeneca  Jan 01, 2019  1 year ago
AstraZeneca announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines.   The Functional Genomics Centre will further develop CRISPR technology to better understand the biology of cancer, creating biological models that may be more reflect...
Source: Roche  Nov 05, 2018  1 year ago
 • The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil  • Data will be submitted to health authorities and presented at an upcoming medical meeting     Basel, 1 November 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the randomised phase III CLL14 study, whi...
Source: Merck  Oct 30, 2018  1 year ago
Merck Today Announced The 24-Week Results Of The Phase II Study Of Evobrutinib In Patients With Relapsing Multiple Sclerosis (Rms) In Berlin, Germany. Evobrutinib First Bruton’s Tyrosine Kinase inhibitor (BTKi) demonstrating clinical proof-of-concept in relapsing multiple sclerosis (RMS) Study met primary endpoint demonstrating significant reduction in Gd+ enhancing T1 lesions on MRI wi...
Source: AstraZeneca  Oct 30, 2018  1 year ago
Data show Lokelma maintained normokalaemia during days 8-29 of the maintenance phase in patients from four Asian countries   AstraZeneca today presented the results from the HARMONIZE Global Phase III trial, which investigated the safety and efficacy of Lokelma (sodium zirconium cyclosilicate) vs. placebo in patients with hyperkalaemia in Japan, Korea, Taiwan and Russia. The resul...
Source: Baze  Oct 03, 2018  2 years ago
Lifestyle Brand Introduces Innovative Customized Health Experience to Combat Nutritional Deficiencies SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Baze, a lifestyle brand focusing on personalized health, has launched the Baze Starter Kit, a simple and affordable, fully-tailored experience designed to combat nutrient deficiencies. The Baze Starter Kit combine...

Please help support this site by donating via paypal options below:

Make a Donation


Source: Thailand Coronavirus News
Mar 05, 2020  1 month ago
Source: Thailand Medical News
Feb 11, 2020  2 months ago
Source: Thailand Medical News
Feb 05, 2020  2 months ago
Source : Thailand Medical news
Feb 05, 2020  2 months ago
Source: Thailand Medical News
Feb 02, 2020  2 months ago

Interesting Reads

Source: Thailand Medical News
Mar 21, 2020  19 days ago
Source: Covid-19 Treatments And Drugs News
Mar 20, 2020  20 days ago
Source: SARS-Cov-2 Coronavirus Research
Mar 08, 2020  1 month ago
Source: Thailand Medical News
Mar 04, 2020  1 month ago
Source: Coronavirus Diagnosis News
Feb 29, 2020  1 month ago
Source: Thailand Medical News
Feb 28, 2020  1 month ago
Source: Thailand Medical News
Feb 23, 2020  2 months ago
Source:Thailand Medical News
Feb 22, 2020  2 months ago
Source: Thailand Medical News
Feb 19, 2020  2 months ago
Source: Thailand Medical News
Feb 13, 2020  2 months ago
Source: Thailand Medical News
Feb 13, 2020  2 months ago
Source : Thailand Medical News
Feb 11, 2020  2 months ago
Source: Thailand Medical News
Feb 10, 2020  2 months ago
Source: Thailand Medical News
Feb 09, 2020  2 months ago
Source: Thailand Medical News
Feb 07, 2020  2 months ago